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Prion Protein of 106 Residues Creates
an Artificial Transmission Barrier
for Prion Replication in Transgenic Mice
NMR studies of recombinant PrPs revealed three a
helices designated HA, HB, and HC (Riek et al., 1996;
Donne et al., 1997; James et al., 1997) with helices HB
and HC corresponding to two of the predicted helices
in a computational model of PrPC (Huang et al., 1994).
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Prior to the availability of the NMR data, we used aStanley B. Prusiner,1,3 and Michael Scott1,6
four-helix-bundle model of PrPC (Huang et al., 1994) to1 Department of Neurology and
construct proteins with each of the predicted helicalInstitute for Neurodegenerative Diseases
regions deleted. When these constructs were expressed2 Department of Pathology
in scrapie-infected neuroblastoma (ScN2a) cells, prote-3 Department of Biochemistry and Biophysics
ase-resistant PrP seemed to be produced in only ScN2a4 Department of Medicine
cells expressing chimeric MHM2PrP(D23±88,D141±176)5 Department of Cellular and Molecular Pharmacology
in which residues 23±88 as well as 141±176 were de-University of California
leted, producing a PrP of 106 residues (Muramoto et al.,San Francisco, California 94143-0518
1996).
Based on the foregoing results, we expanded Tg lines
of mice expressing PrP106 (Muramoto et al., 1997); theySummary
remained healthy for more than 500 days of age but
were highly susceptible to RML miniprions containingA redacted prion protein (PrP) of 106 amino acids with
homologous PrPSc106. Several lines of evidence arguetwo large deletions was expressed in transgenic (Tg)
that PrP106 exists in a conformation that is differentmice deficient for wild-type (wt) PrP (Prnp0/0) and sup-
from PrPC and that it may embody a PrP* state whichported prion propagation. RML prions containing full-
is an intermediate in the pathway of PrPSc formation.length PrPSc produced disease in Tg(PrP106)Prnp0/0 mice
Our demonstration that z50% of the PrP residues mayafter z300 days, while transmission of RML106 prions
be removed and yet the remaining polypeptide can sup-containing PrPSc106 created disease in Tg(PrP106)
port PrPSc formation suggests that further mutagenesisPrnp0/0 mice after only z66 days on repeated passage.
of the PrP gene may render these miniprions more ame-This artificial transmission barrier for the passage of
nable to biophysical analysis.RML prions was diminished by the coexpression of
wt MoPrPC in Tg(PrP106)Prnp1/0 mice that developed
Resultsscrapie in z165 days, suggesting that wt MoPrP acts
in trans to accelerate replication of RML106 prions.
Transmission of Mouse Prions to Tg(PrP106) MicePurified PrPSc106 was protease resistant, formed fila-
RML prions containing full-length wt MoPrPSc producedments, and was insoluble in nondenaturing deter-
signs of CNS dysfunction between 200 and 400 daysgents. The unique features of RML106 prions offer
after intracerebral inoculation in Tg(PrP106)4290/Prnp0/0insights into the mechanism of prion replication, and
mice (Figure 1). The mean incubation time was z300the small size of PrPSc106 should facilitate structural
days, while Tg(PrP106)4280/Prnp0/0 mice expressinganalysis.
z8-fold less PrP106 developed signs of CNS dysfunc-
tion at z500 days (Table 1).Introduction
Brain homogenates prepared from Tg(PrP106)4290/
Prnp0/0 mice with CNS dysfunction z250 days after inoc-Conversion of cellular prion protein (PrPC) into the dis-
ulation with RML prions were inoculated into weanlingease-causing isoform (PrPSc) is the central pathogenic
Tg(PrP106)4290/Prnp0/0 mice, all of which developedprocess in the prion diseases (Prusiner et al., 1998). The
neurologic disease between 50 and 80 days later (Figuredifficulties in determining the structure of PrPSc have
1). On second passage, RML106 prions produced similarprompted efforts to determine the minimal size of the
incubation times.PrP fragment that supports PrPSc formation. Deletions
We refer to the initial prolongation of incubation timeof the N-terminal 67 amino acid residues of PrP formed
as a ªprion transmission barrier.º This barrier is equiva-PrPSc in scrapie-infected cultured cell studies (Rogers
lent to the naturally occurring ªspecies barriersº firstet al., 1993). N-terminally truncated PrPSc, designated
described more than three decades ago (Pattison, 1965).PrP 27±30, is infectious (Prusiner et al., 1984), and sub-
In both instances, there is a PrP sequence-dependentsequent studies with transgenic (Tg) mice showed that
restriction on prion transmission that manifests as amany but not all of these N-terminal residues could be
prolongation of the incubation time (Scott et al., 1989).deleted without preventing prion propagation (Fischer
When the sequence of PrPSc in the inoculum matcheset al., 1996).
that of PrPC expressed in the recipient mouse, a pro-
nounced reduction in the length of the incubation time
6 To whom correspondence should be addressed.
has been observed (Prusiner et al., 1990).7 Present address: Tohoku University School of Medicine, Depart-
This transmission barrier was also evident whenment of Neurological Sciences, Sendai 980, Japan.
RML106 miniprions were inoculated into Tg(MoPrP-8 Present address: Statens Serum Institute, Department of Immunol-
ogy, DK-2400 Copenhagen, Denmark. A)4053/Prnp0/0 mice that routinely develop scrapie z50
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ameter vacuoles, of the stratum radiatum in four of seven
mice (Figure 2D). In the remaining three mice, infrequent
vacuoles were less than 5 mm in diameter, but there was
severe loss of nerve cell bodies in the pyramidal cell
layer of the hippocampus. In all seven mice, there was
intense reactive astrocytic gliosis (Figure 2E). It is note-
worthy that the diminished vacuolation in Creutzfeldt-
Jakob disease (CJD) has been correlated with the loss
of neurons in human brain (Masters and Richardson,
1978).
On second passage, RML106 prions produced mild
or no vacuolation in the hippocampal stratum radiatum
in association with severe loss of pyramidal neurons
(Figure 2G), but reactive astrocytic gliosis was intense
(Figure 2H) in all four mice examined. The extreme lossFigure 1. Incubation Times in Tg(PrP106)Prnp0/0 Mice Inoculated
of pyramidal cell neurons (.80%) was confined largelywith Wild-Type or Miniprions
to the CA1 region of the hippocampus. Fewer nerveTg(PrP106)Prnp0/0 mice were inoculated with wild-type RML prions
(open circles) that were previously passaged in Prnpa/a CD-1 mice. cells disappeared in the CA2 and CA3 regions, and no
From ill Tg(PrP106)Prnp0/0 mice, brains containing RML106 prions detectable loss occurred in the dentate gyrus (data not
composed of PrPSc106 were harvested and homogenates prepared shown). There was only mild vacuolation of white matter
for subsequent passage. First passage RML106 prions were inocu- tracts in Tg(PrP106) mice inoculated with RML106 pri-
lated into Tg(PrP106)Prnp0/0 mice and the incubation times recorded
ons in contrast to non-Tg mice inoculated with RML(open triangles). The above scenario was repeated to produce sec-
prions in which white matter vacuolation is often striking.ond passage RML106 prions (filled squares).
Similar neuropathological changes were found in four
Tg(PrP106)4290/Prnp1/0 mice during the first passage
of RML106 prions (data not shown).days after inoculation with RML prions containing wt
PrPSc (Table 2). At more than 400 days after inoculation
with RML106 miniprions, the Tg(MoPrP-A)4053/Prnp0/0 PrPSc106 in Tg(PrP106)Prnp0/0 Mice
Western blots of brain homogenates of Tg(PrP106)mice remained well.
Prnp0/0 mice with signs of CNS dysfunction showed sub-
stantial amounts of PrPSc106 that resisted limited diges-Neuropathology of Tg(PrP106) Mice
Tg(PrP106)4290/Prnp0/0 mice inoculated with RML pri- tion with proteinase K (Figure 3). Both untreated and
proteinase K±digested PrP106 migrated predominantlyons previously passaged in non-Tg CD-1 mice exhibited
neuropathologic changes characteristic of experimental as a single, diffuse band with an apparent molecular
weight of z22 kDa on SDS-PAGE. The lack of an electro-scrapie. Both gray matter vacuolar degeneration and
intense reactive astrocytic gliosis were found (data not phoretic mobility shift in PrPSc106 after limited digestion
with proteinase K was expected because N-terminalshown). When Tg(PrP106)4290/Prnp0/0 mice were inocu-
lated with RML106 prions, they displayed moderately truncation of PrPSc occurs near residue 89 (Basler et al.,
1986; Prusiner et al., 1984), which is at the N terminussevere vacuolation, consisting of multiple 5±20 mm di-
Table 1. Passage of RML Prions in Mice Expressing Wt MoPrP-A as Well as Chimeric MHM2, MHM2 (D23±88), and PrP106
Transgene No. of Copies Incubation Period
Host Expression Levela of MoPrP-A Inocula (Days 6 SEM) n/n0
Prnp0/0 0 0 RML .600 0/12
Prnp1/0 0 1 RML 426 6 18b 9/9
FVB 0 2 RML 127 6 1 50/50
Tg(MHM2)294/Prnp0/0 103 0 None .700 0/10
103 0 RML 133 6 9 10/10
Tg(MHM2)294/Prnp1/0 103 1 RML 130 6 1 10/10
Tg(MHM2,D23±88)9380/Prnp0/0 0.53 0 None .700c 0/7
0.53 0 RML .700 0/8
Tg(MHM2,D23±88)9381/Prnp0/0 43 0 None .400 0/9
43 0 RML .500c 0/6
Tg(MHM2,D23±88)9381/Prnp1/0 43 1 RML 257 6 6 7/7
Tg(PrP106)4280/Prnp0/0 13 0 None .500c 0/9
13 0 RML 508 6 40 8/8
Tg(PrP106)4290/Prnp0/0 83 0 None .500c 0/7
83 0 RML 300 6 22 18/18
Tg(PrP106)4290/Prnp1/0 83 1 RML 165 6 10 8/8
a Expression levels were determined by comparing serial dilutions of brain homogenates with normal Syrian hamster brain by Western blot.
b Data from Prusiner et al., 1993.
c A few mice developed neurological signs at ages .400 days, but neuropathological evaluation revealed only age-related changes, and no
PrPSc was detected by Western blot.
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Table 2. Prion Transmission Barrier between Mice Expressing MoPrP-A and PrP106
Inocula Tg(PrP106) 4290/Prnp0/0 Tg(MoPrP-A) 4053/FVB Tg(PrP106) 4290/Prnp1/0
None .500 (0/7)a .700 (0/20) .450 (0/9)b
RML 300 6 22 (8/8) 50 6 2 (16/16) 165 6 10 (8/8)
Tg4053(RML) ND 58 6 2 (7/7) ND
RML106(RML) 66 6 3 (40/40) .420 (0/10)b 83 6 6 (20/20)
RML106(RML106) 66 6 6 (10/10) ND ND
Values are days 6 SEM (n/n0).
ND, not determined.
a A few mice developed neurological signs at ages .400 days, but neuropathological evaluation revealed only age-related changes, and no
PrPSc was detected by Western blot.
b Ongoing experiments.
of PrP106. Western blot analysis of brain homogenates homogenates of the brains of Tg(PrP106)4290/Prnp0/0
mice with scrapie. The homogenates were extractedfrom animals receiving serially passaged RML106 prions
also revealed the presence of proteinase K±resistant with 2% (w/v) Sarkosyl and centrifuged at 120,000 3 g
for 1 hr at 48C. All of the PrPSc106 was found in the pelletPrPSc106 (Figure 3).
Using a conformation-dependent immunoassay (CDI) fraction, and no PrPSc106 was found in the supernatant
(data not shown).(Safar et al., 1998), we measured PrPSc106 in 5% (w/v)
Figure 2. Tg(PrP106)Prnp0/0 Mice Exhibit the
Neuropathologic Hallmarks of Prion Disease
(A, D, and G) Hematoxylin and eosin stain.
Py, pyramidal cells of the CAI region of the
hippocampus. SR, stratum radiatum (con-
tains apical dendritic trees of pyramidal
neurons).
(B, E, and H) GFAP immunohistochemistry for
astrocytes.
(A and B) Control uninoculated Tg(PrP106)
Prnp0/0 mouse showed no evidence of vacuo-
lar degeneration, nerve cell loss, or reactive
astrocytic gliosis.
(D and E) Tg(PrP106)Prnp0/0 mice inoculated
with first passage RML106 prions showed
vacuolar degeneration, nerve cell loss, and
reactive astrocytic gliosis.
(G and H) Tg(PrP106)Prnp0/0 mice inoculated
with second passage RML106 prions exhib-
ited less intense vacuolar degeneration,
much greater nerve cell loss, and more severe
reactive astrocytic gliosis than in (D) and (E).
(C, F, and I) PrP immunohistochemistry with
the 3F4 mAb using the hydrolytic autoclaving
technique. (C) punctate PrP immunopositive
deposits in the gray matter of Tg(PrP106)
Prnp0/0 mice. (F and I) reduction in the larger
punctate PrP immunopositive deposits in the
gray matter of scrapie-infected Tg(PrP106)
Prnp0/0 mice. (I) There are larger deposits as-
sociated with astrocytes in the pyramidal cell
layer and diffuse, small deposits (1±3 mm)
throughout the stratum radiatum.
All of the photomicrographs show the same
region of the CAI region with the pyramidal
cell layer at the top. Bar in (I) is 50 mm and
applies to all photomicrographs.
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Figure 3. Immunoblot of PrPSc106 in Brains of Tg(PrP106)Prnp0/0
Mice
Rodents exhibiting neurologic signs of prion disease were sacri-
ficed, and brain homogenates were prepared. Controls at 200 days
of age were prepared similarly. Minus (2) symbol denotes undi-
gested, control sample, and plus (1) symbol designates sample
Figure 4. Immunoblot of PrPSc Molecules in Brains of Tg(MHM2,subjected to limited proteolysis. Samples were digested with 20
D23±88) and Tg(PrP106) Micemg/ml of proteinase K for 60 min at 378C at a protein to proteinase
K ratio of 50:1. After SDS-PAGE, Western blotting was performed Mice exhibiting neurologic signs of prion disease were sacrificed,
with 3F4 mAb at 1:5000 dilution. Paired sample lanes are numbered as and brain homogenates were prepared. Controls at 440 days of
follows: (1) normal Syrian hamster, (2) scrapie-infected Syrian ham- age were prepared similarly. Minus (2) symbol denotes undigested,
ster, (3) uninoculated Tg(PrP106)Prnp0/0 mouse, (4 and 5) Tg(PrP106) control sample, and plus (1) symbol designates sample subjected
Prnp0/0 mice inoculated with RML prions, (6 and 7) Tg(PrP106)Prnp0/0 to limited proteolysis. Samples that were digested with 20 mg/ml of
mice inoculated with RML106 prions. Apparent molecular weights proteinase K for 60 min at 378C at a protein to proteinase K ratio
based on migration of protein standards are given in kilodaltons. of 50:1. After SDS-PAGE, Western blotting was performed with 3F4
mAb at 1:5000 dilution. Paired sample lanes are numbered as fol-
lows: (1) uninoculated Tg(MHM2,D23±88)Prnp0/0 mouse, (2) Tg(MHM2,
D23±88)Prnp0/0 mouse inoculated with RML prions, (3) uninoculated
Uninoculated Tg(PrP106)Prnp0/0 Mice Tg(MHM2,D23±88)Prnp1/0 mouse, (4) Tg(MHM2,D23±88)Prnp1/0 mouse
Tg(PrP106)4290/Prnp0/0 mice remained healthy for .500 inoculated with RML prions, (5) uninoculated Tg(PrP106)Prnp0/0
mouse, (6) Tg(PrP106)Prnp0/0 mouse inoculated with RML prions, (7)days without showing any signs of spontaneous disease
uninoculated Tg(PrP106)Prnp1/0 mouse, and (8) Tg(PrP106)Prnp1/0(Table 2), confirming that prion transmission, and not a
mouse inoculated with RML prions. Apparent molecular weightsspontaneous disease caused by transgene expression,
based on migration of protein standards are given in kilodaltons.
was responsible for the highly synchronous onset of neu-
rologic signs observed when Tg(PrP106)4290/Prnp0/0
mice were infected with RML106 miniprions (Figure 1).
RML prions produced disease in z165 days, which rep-Neurohistological examination of three uninoculated,
resents a nearly 50% reduction in the length of the incu-clinically normal Tg(PrP106)4290/Prnp0/0 mice about 90
bation time (Table 2). That PrPSc106 was produced indays of age showed none of the features characteristic
Tg(PrP106)4290/Prnp1/0 mice was evident by Westernof prion disease, such as vacuolar degeneration of gray
blotting using 3F4 mAbs (Figure 4, lane 8). The brains ofor white matter and reactive astrocytic gliosis (Figures
Tg(PrP106)4290/Prnp1/0 mice inoculated with RML pri-2A and 2B). Immunohistochemistry using the anti-PrP
ons contained both MoPrPSc and PrPSc106, as deter-3F4 monoclonal antibody (mAb) revealed abnormal,
mined by ELISA using antibodies that distinguish MoPrP-Apunctate PrP deposits in the gray matter (Figure 2C).
from PrP106 and bioassays in Tg(PrP106) mice and nor-These were round to oval and varied from 1 to 10 mm
mal mice, whereas the brains of Tg(PrP106)Prnp1/0 micein diameter. None appeared to be within nerve cell bod-
inoculated with RML106 prions contained only PrPSc106ies nor within the cell bodies or processes of astrocytes,
(data not shown). Regardless of inoculum, all scrapie-based on double immunostaining of the latter with glial
affected Tg(PrP106)4290/Prnp1/0 mice displayed thefibrillary acidic protein (GFAP)-specific antibodies (data
same distinctive neuropathological features, includingnot shown). They appeared to be distributed along the
neuronal death in the CA1 region of the hippocampusdendritic trees of Purkinje cells and scattered among
seen in scrapie-affected Tg(PrP106)Prnp0/0 mice.the dendrites of other nerve cells in the hippocampus
(Figure 2C), basal ganglia, and cerebral cortex (data
Properties of RML106 Miniprions from Tgnot shown). In sections through the midthalamus, they
Mouse Brainsappeared to be confined largely to the ventral lateral
We purified PrPSc106 from scrapie-affected Tg(PrP106)group of nuclei that receives sensory and motor system
Prnp0/0 mouse brains utilizing detergent extraction fol-afferents. Their size and location in gray matter suggest
lowed by a discontinuous sucrose gradient (Prusinerthey might represent deposits of mutated PrP in axon
et al., 1982). When rapidly sedimenting fractions wereterminals and presynaptic boutons.
negatively stained and examined by electron micros-
copy, numerous rod-shaped particles were found that
resembled prion rods composed of PrP 27±30 (FiguresEvidence for trans-Acting PrP
The transmission barrier for RML prions containing wt 5A and 5B). Whether the rods composed of PrPSc106
possess the tinctorial properties of amyloid, as do thePrPSc in Tg(PrP106)4290 mice was dramatically reduced
when these mice carried a single copy of the wt MoPrP rods composed of PrP 27±30, remains to be established
(Prusiner et al., 1983). Larger quantities of purifiedgene. Inoculation of Tg(PrP106)4290/Prnp1/0 mice with
Artificial Miniprions
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Figure 5. Ultrastructure and Optical Spectroscopy of PrPSc106
(A) Prion rods composed of PrP 27±30 were purified from the brains
of scrapie-infected Syrian hamsters displaying signs of neurologic
dysfunction.
(B) Prion rods composed of PrPSc106 were purified from the brains of
scrapie-infected Tg(PrP106)Prnp0/0mice showing CNS dysfunction.
Negatively stained with 2% ammonium molybdate. Bar, 100 nm.
(C) FTIR spectra of two different populations of PrPSc106 aggregates
Figure 6. Characteristics of Recombinant PrP106 Expressed inobserved in fractions prepared from discontinuous sucrose gradi-
E. colients. Both sets of spectra were readily reproducible as seen from
the two independent measurements shown. rPrP106 was purified and refolded from GdnHCl.
(A) Far-UV circular dichroism spectra of rPrP106 (solid line) and
SHa(90±231) (dashed line) at pH 5.5.
PrPSc106 are needed in order to determine whether (B) FTIR spectra of PrP106. Deconvolutions yielded estimates of
Congo red dye binds and exhibits birefringence. Fou- 36% a helix and 31% b sheet at p2H 5.5 (solid line); 25% a helix
and 46% b sheet at p2H z6.3 (dotted line); 29% a helix and 39% brier transform infrared (FTIR) spectroscopy of purified
sheet at p2H 7.5 (dashed line).PrPSc106 revealed two populations, which may repre-
(C) Ultrastructure of spherical aggregates of rPrP106 measuring z9sent sample heterogeneity created by intermolecular
nm in diameter. Negatively stained with 2% uranyl acetate. Bar,
interactions (Figure 5C). Deconvolution yielded esti- 100 nm.
mates of 31% a helix and 36% b sheet for one population
(solid line), and 27% a helix and 37% b sheet for the
other (dashed line). (Mehlhorn et al., 1996). Whereas rSHaPrP(90±231) gave
a spectrum indicative of a high level of a helix withEncouraged by the results of earlier studies, in which
PrP106 expressed in ScN2a cells was found to be prote- minima at 208 and 221 nm, rPrP106 gave a spectrum
consistent with a high level of b sheet, with a minimumase resistant but soluble in 0.5% Sarkosyl, we attempted
to solubilize PrPSc106 from the brains of Tg(PrP106) at 216 nm. FTIR spectroscopy of recombinant PrP106
yielded estimates of 25%±36% a helix and 31%±46%Prnp0/0 mice using concentrations of Sarkosyl varying
from 0.5% to 10%. A large number of additional anionic, b sheet depending upon the pH (Figure 6B). The refolded
rPrP106 also displayed a partial resistance to proteinasecationic, and nonionic detergents that were used either
alone or in combination in earlier studies were also inef- K digestion, which is also consistent with the propensity
to form a structure rich in b sheet (data not shown).fective (Wille and Prusiner, 1999).
Although refolded rPrP106 appeared soluble at a con-
centration of 10 mg/ml, the protein formed relativelyPrP106 Prefers a b Sheet Conformation
Recombinant (r) PrP106 and SHaPrP(90±231) were ex- uniform spherical particles of z9 nm in diameter (Figure
6C); no rod-shaped polymers were seen as in the casepressed in E. coli, purified by chromatography, dena-
tured with 8 M guanidinium HCl, refolded by rapid dilu- of PrPSc106 (Figure 5B). While optical spectroscopic
measurements cannot readily differentiate rPrP106 fromtion, and analyzed by CD spectroscopy (Figure 6A)
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Figure 7. Expression of PrP106 in Control
and Scrapie-Infected Neuroblastoma Cells
Control (N2a) or scrapie-infected (ScN2a)
cells were transfected transiently with the
SPOX expression vector carrying modified
PrP genes as noted below.
(A) Uninfected N2a cells digested with 20
mg/ml proteinase K for 60 min at 378C.
(B) Infected ScN2a cells digested with 20 mg/ml
proteinase K.
(C) Uninfected N2a cells digested with 7
mg/ml proteinase K for 30 min at 378C.
(D) Infected ScN2a cells digested with 7 mg/ml
proteinase K.
Minus (2) symbol denotes undigested, con-
trol sample, and plus (1) symbol designates
sample subjected to limited proteolysis.
Samples that were digested with either 7 or
20 mg/ml of proteinase K correspond to protein to proteinase K ratios of 71:1 or 25:1, respectively. After SDS-PAGE, Western blotting was
performed with 3F4 mAb at 1:5000 dilution. Paired sample lanes are numbered as follows: (1) MHM2, (2) MHM2(D23±88), (3) MHM2(D23±88,D141±
155), (4) MHM2(D23±88,D141±164), (5) PrP106, and (6) mock transfection. Apparent molecular weights based on migration of protein standards
are given in kilodaltons.
PrPSc106, the quartenary structures of the two proteins shorter length: D141±155 and D141±164. The larger the
internal deletion, the greater the resistance to limitedwere markedly different as judged by negative stain
electron microscopy. proteolytic digestion by proteinase K when performed
with 7 mg/ml for 30 min at 378C on homogenates from
either ScN2a (Figure 7D, lanes 3±5) or uninfected N2aProtease-Resistant PrP106 in N2a Cells
In earlier studies, a fraction of PrP106 expressed in cells (Figure 7C, lanes 3±5).
ScN2a cells was found to be protease resistant and
soluble in 0.5% Sarkosyl (Muramoto et al., 1996). While Tg(MHM2,D23±88) Mice
While our data show that PrP106 was converted intoMoPrPC in ScN2a cells was soluble in 0.5% NP40 and
0.5% sodium deoxycholate, neither PrP106 nor MoPrPSc PrPSc in Tg(PrP106) mice inoculated with RML or RML106
prions (Figure 2), we were unable to identify clearlywas soluble under these conditions. The relative insolu-
bility of PrP106 and its resistance to limited digestion PrPSc106 in ScN2a cells infected with RML prions. Our
results obtained with Tg(MHM2,D23±88) mice may pro-by proteinase K in ScN2a cells suggested that this pro-
tein was similar to PrPSc but soluble in Sarkosyl under vide insight into the reasons for this apparent dichot-
omy. In ScN2a cells converting MoPrPC into MoPrPSc,conditions that did not inactivate prion infectivity.
In view of the foregoing results, we became concerned MHM2(D23±88) was readily converted into PrPSc (Rogers
et al., 1993), but Tg(MHM2,D23±88)Prnp0/0 mice inocu-by the insolubility of PrPSc106 from the brains of Tg(PrP106)
Prnp0/0 mice extracted with Sarkosyl. Using a procedure lated with Mo RML prions remained resistant to infection
for more than 500 days (Table 1). That this behavior canthat allowed close approximation of mutant PrP expres-
sion from transfected PrP constructs in scrapie-infected be attributed to the N-terminal deletion (D23±88) can be
seen from the fact that control Tg(MHM2)Prnp0/0 miceand control cultured cells, we found similarly low levels
of protease-resistant PrP106 in N2a and ScN2a cells inoculated with RML prions did develop CNS dysfunc-
tion in z120 days. In contrast, Tg(PrP106)Prnp0/0 mice(Figures 7A and 7B, lane 5). Cell homogenates were
immunoblotted before and after digestion with 20 mg/ were susceptible to RML prions containing wt MoPrpSc,
suggesting that the second deletion (D141±176) allevi-ml of proteinase K for 1 hr at 378C. The ratio of total
protein (500 mg) in the homogenate to proteinase K (20 ates the extreme dependence on trans-acting PrP
caused by the N-terminal deletion.mg) in the digestion reaction was 25:1. A subpopulation
of protease-resistant PrP106 in N2a and ScN2a cells Neurohistological examination of two uninoculated
Tg(MHM2,D23±88)Prnp0/0 animals sacrificed at 440 days(Figures 7C and 7D, lane 5) was evident when digestion
was performed with 7 mg/ml of proteinase K for 30 min of age revealed no abnormalities. Immunohistochemis-
try using the 3F4 mAb revealed no PrP deposits inat 378C. In this case, the ratio of homogenate protein to
proteinase K was 71:1. Wild-type PrPC and PrPC(D23±88) Tg(MHM2,D23±88)Prnp0/0 mice. This contrasts with the
punctate PrP deposits in the gray matter of Tg(PrP106)were completely hydrolyzed under these conditions
(Figure 7C, lanes 1 and 2). Prnp0/0 mice seen after hydrolytic autoclaving (Fig-
ures 2C).Because full-length MHM2PrP and N-terminally trun-
cated MHM2PrP(D23±88) expressed in ScN2a (Figures Since MHM2(D23±88) was readily converted into PrPSc
in ScN2a cells that also express wt MoPrPC, we asked7B and 7D, lanes 1 and 2) but not in control N2a cells
(Figures 7A and 7C, lanes 1 and 2) acquired protease whether Tg(MHM2,D23±88)9381/Prnp1/0 mice express-
ing both MHM2(D23±88) and MoPrPC might be moreresistance, we concluded that the deletion of internal
residues 141±176 must be responsible for the anoma- susceptible to RML prions than Tg(MHM2,D23±88)9381/
Prnp0/0 mice. Indeed, Tg(MHM2,D23±88)9381/Prnp1/0lous behavior of PrP106 with respect to detergent solu-
bility and protease resistance. To further probe this is- mice developed CNS disease z260 days after inocula-
tion with RML prions (Table 1). As in the case ofsue, we created two additional internal deletions of
Artificial Miniprions
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Tg(PrP106)Prnp1/0 mice, this finding argues that full- MoPrPC or MoPrPSc act in trans to accelerate the forma-
tion of PrPSc106 or MHM2PrPSc(D23±88) will be impor-length wt MoPrP acts in trans to accelerate the conver-
sion of MHM2(D23±88) into PrPSc. tant. Does MoPrPC bind to PrP106 and facilitate PrPSc106
formation, or does nascent MoPrPSc act on PrP106 toIn the brains of Tg(MHM2,D23±88)Prnp0/0 mice inocu-
lated with RML prions and sacrificed 300 days after accelerate PrPSc106 formation? In the latter scenario,
the production of wt MoPrPSc in Prnp1/0 mice drivesinoculation, no PrPSc could be detected by Western blot-
ting (Figure 4, lane 2). The transgene construct contained conversion of the transgene product by providing a
source of the PrPSc template. In the former scenario, avidno mutations upon resequencing; it was expressed appro-
priately, and the transgene product was glycosylated at binding of MoPrPC to protein X might facilitate PrPSc106
formation. Determining whether the action of MoPrP inN-linked consensus sites and anchored by a C-terminal
glycosylphosphatidyl inositol (GPI) moiety (data not trans is concentration dependent will be of considerable
interest. Moreover, with the serial propagation of RML106shown). In Tg(MHM2,D23±88)Prnp1/0 mice inoculated
with RML prions, protease-resistant MHM2PrPSc(D23± prions, MoPrPC may cause a prolongation of incubation
period in Tg(PrP106)Prnp1/0 mice relative to Tg(PrP106)88) was detected by Western blotting using the 3F4 mAb
(Figure 4, lane 2). Prnp0/0 mice (Table 2).
Deletion MutationsDiscussion
We initially deleted the N-terminal residues 23±88 be-
cause limited proteolysis removes these amino acidsThe studies reported here with PrP106 establish that
from PrPSc without altering prion infectivity (Prusiner etresidues 23±88 and 141±176 including helix A do not play
al., 1984; Basler et al., 1986). Although MHM2(D23±88)a critical role in the formation of PrPSc, transmissibility of
was readily converted into a protease-resistant isoformprions, or pathogenesis of prion disease. PrPSc106 and
in ScN2a but not N2a cells (Rogers et al., 1993), it was notadditional variants may prove amenable to biophysical
converted into PrPSc in Tg(MHM2,D23±88)Prnp0/0 miceanalysis.
inoculated with RML prions (Table 1). In contrast,
Tg(MoPrP,D32±80)Prnp0/0 and Tg(MoPrP,D32±92)Prnp0/0
mice, both of which preserved the 10 N-terminal aminoPrion Transmission Barrier
acids, readily produced PrPSc after inoculation with RMLThe development of Tg mice for prion studies led to the
prions (Fischer et al., 1996; Shmerling et al., 1998). Be-discovery that the species barrier is due to differences
sides the addition of these ten amino acids from the Nin the amino acid sequence of PrPSc in the inoculum and
terminus of PrP, the deletion of an additional 36 aminoPrPC expressed in the recipient animal (Scott et al., 1989,
acids from the interior of MHM2(D23±88) to produce1997). We propose that when artificial PrP sequences
PrP106 also rendered PrP more susceptible to transfor-are expressed and create a barrier for transmission of
mation into PrPSc. It will be important to learn whetherprions that this be designated a prion transmission bar-
smaller deletions of 15 and 24 amino acids from therier. Like the species barrier, differences in PrP se-
interior of MHM2(D23±88) to produce MHM2(D23±88,quence act to restrict the transmission of prions with a
D141±155) and MHM2(D23±88,D141±164) (Figure 7C),particular PrPSc sequence to an animal expressing PrPC
respectively, facilitate or impede the formation of PrPScwith another sequence. Additional factors, including the
after inoculation with a variety of preparations includingconcentration of PrPC in the recipient mouse (Prusiner
RML and RML106 prions.et al., 1990), level of protease-sensitive PrPSc associated
with a particular prion strain (Safar et al., 1998), and the
host-specific factor, provisionally designated protein X PrP* and Protein X
(Telling et al., 1995; Kaneko et al., 1997), have been The resistance of PrP106 expressed in N2a and ScN2a
shown to modify incubation times. cells to limited digestion with 7 mg/ml of proteinase K
for 30 min at 378C (Figures 7C and 7D) as well as its
insolubility in 0.5% NP40 and 0.5% deoxycholate argues
trans-Acting PrP in Prion Propagation that a subset of PrP106 molecules possesses some
The prolonged incubation times observed with RML pri- of the characteristics of PrPSc. Whether this subset of
ons inoculated into Tg(PrP106)Prnp0/0 and Tg(MHM2,D23± PrP106 is further along the pathway toward formation
88)Prnp0/0 mice led to the discovery of trans-acting PrP, of PrPSc than is wt PrPC is uncertain; however, PrP106
which accelerates prion replication (Table 1). The incu- is clearly eligible for conversion into PrPSc106, since it
bation periods of Tg(PrP106)Prnp1/0 and Tg(MHM2,D23± efficiently transmits disease to recipient Tg(PrP106)
88)Prnp1/0 mice inoculated with Mo RML prions were Prnp0/0 mice. The term PrP* is used here to describe
significantly shorter than those of Prnp1/0 mice that are metastable intermediates of PrPC that lie along the path-
hemizygous for PrP gene ablation and have incubation way of PrPSc formation (Prusiner et al., 1998). It seems
times exceeding 400 days (Prusiner et al., 1993; BuÈ eler likely that the structure of PrPC changes when it binds
et al., 1994; Carlson et al., 1994). It appears that the to protein X and that this is the rate-limiting step in PrPSc
products of RML replication directed by the single copy formation under most circumstances (Kaneko et al.,
of MoPrP are driving the production of PrP106 prions, 1997).
thereby acting in trans to accelerate the passage across Whether PrP106 exists in a PrP* state that does not
the prion transmission barrier. require protein X for conversion into PrPSc106 or that it
binds to protein X with an altered avidity that facilitatesElucidating the mechanism whereby low levels of wt
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PrPSc106 formation remains to be established. Two of into Tg(PrP106)Prnp0/0 mice required z300 days (Table
1), it is unsurprising that transiently expressed PrP106the four residues thought to form the protein X±binding
site on the surface of PrPC are deleted in PrP106 (Kaneko in ScN2a cells was not converted into PrPSc106 during
the 3 day duration of the experiment (Figure 7B, lane 5).et al., 1997). It is also important to consider the alterna-
tive possibility that a large fraction of the PrP106 poly-
peptide adopts an aberrant conformation, and that the Novel Approaches Arising from This Research
partial protease resistance observed in normal N2a cells The successful production of miniprions suggests that
is attributable to aggregation of misfolded PrP106. We even smaller prions can be designed. While PrPSc106 is
do not consider this very likely for two major reasons. insoluble in a variety of detergents, its small size may
First, it is clear that PrP106 readily functions as a tem- allow us to design derivatives that are soluble by substi-
plate for the de novo production of prions. The incuba- tuting surface residues with hydrophilic side chains.
tion period of z65 days observed in Tg(PrP106) mice While this is laborious when the constructs must be
infected with PrP106 prions is comparable to the short- tested in Tg mice, preliminary studies with mutant PrPs
est incubation periods observed in Tg mice expressing expressed in N2a cells and E. coli may expedite investi-
wild-type PrP genes (Prusiner et al., 1990; Scott et al., gations.
1993; Telling et al., 1996a). Given that the incubation The infection of Tg(PrP106)Prnp0/0 mice needs to be
period is generally inversely proportional to PrP expres- expanded using different prion strains. The recognition
sion (Prusiner et al., 1990; Carlson et al., 1994), a short that prion-specified properties of different strains reside
incubation period seems highly unlikely if a majority of in the conformation of PrPSc (Bessen and Marsh, 1994;
the PrP106 formed misfolded aggregates which could not Telling et al., 1996b; Scott et al., 1997; Safar et al., 1998)
be converted into PrPSc. Second, uninfected Tg(PrP106) raises the possibility that a strain other than RML might
Prnp0/0 mice show no evidence of spontaneous disease produce PrPSc106 that is soluble in nondenaturing deter-
attributable to PrP106 expression, in contrast to other gents. Alternatively, the minimal structure of PrP106 may
studies with deletion mutations that caused neuronal limit the diversity of prion strains that can be enciphered.
storage disorders in response to the accumulation of The extreme prion transmission barriers reported here
misfolded PrP in the ER (Muramoto et al., 1997). facilitated our discovery that PrP acts in trans to acceler-
Interestingly, rPrP106 adopts a b sheet structure as ate the replication of prions. Deciphering the molecular
judged by optical spectroscopy when refolded from mechanism responsible for this phenomenon may ad-
GdnHCl under conditions where recombinant SHaPrP vance our understanding of the replication of strain-
(90±231) and SHaPrP(29±231) refold into a-helical struc- specified conformers of PrPSc.
tures. Additionally, PrP106 in a b sheet conformation
forms spherical aggregates of z9 nm in diameter (Figure
Experimental Procedures6C). These findings parallel the production of protease-
resistant PrP106 expressed in cultured N2a cells (Figure
Transgenes in Mice and Cells
7C). Of note, prion rods composed of PrP 27±30 soni- PrP constructs and Tg mice used in this study have been described
cated in 0.1% SDS lose their infectivity and form spheri- previously (Muramoto et al., 1996, 1997). CD-1 and FVB mice were
cal particles z10 nm in diameter (Riesner et al., 1996). obtained from Charles River Laboratories (Wilmington, MA).
Tg(PrP106)Prnp1/0 heterozygotes were generated by crossing ani-By CD spectroscopy, PrP 27±30 lost most of its b sheet
mals from Tg(PrP106)4290/Prnp0/0 line with inbred non-Tg FVB micestructure and acquired a high a-helical content. Treat-
followed by screening the offspring for the transgene.ment of these preparations with acetonitrile increased
the b sheet content and promoted aggregation but failed
Prion Inoculato restore prion infectivity.
RML (Rocky Mountain Laboratory) prions passaged in Swiss mice
were derived as previously described (Chandler, 1961). The MHM2-
adapted RML prion inoculum was generated by passaging RML
PrPSc Formation in Cultured Cells prions in Tg(MHM2)294/Prnp0/0 mice (Scott et al., 1993).
Although PrP106 does display properties resembling
PrPSc as previously described (Muramoto et al., 1996), Scrapie Incubation Periods
the studies reported here emphasize the need to monitor Mice of either sex at age 7±10 weeks were inoculated intracerebrally
carefully the conditions for limited digestion. As we dem- with 30 ml of 1% brain homogenate in phosphate-buffered saline
(PBS) without Ca21 or Mg21 containing 1 mg/ml bovine serum albu-onstrated, some PrPs show a relative resistance to pro-
min. Beginning 50 days after inoculation, mice were examined dailyteinase K digestion yet are distinct from PrPSc (Figure
for neurologic dysfunction (Carlson et al., 1986).7). In earlier work, resistance of PrP to low concentra-
tions of proteinase K was reported (Lehmann and Harris,
Brain Homogenates, Western Blotting, and ELISA1996a, 1996b). Our results highlight the importance of
Brain homogenates (10% w/v) in sterile PBS were prepared by re-
creating controls where the levels of PrP transgene ex- peated extrusion through syringe needles of successively smaller
pression in uninfected cells are similar to those in the size, as previously described (Scott et al., 1989). Homogenates were
infected cells. Most experiments with ScN2a and N2a adjusted to 1 mg/ml protein in 100 mM NaCl, 1 mM EDTA, 0.5%
sodium deoxycholate, 0.5% Triton X-100, and 50 mM Tris-HCl (pHcells have been performed by first infecting N2a cells
7.5). Proteinase K (Boehringer Mannheim, Indianapolis, IL) waswith RML prions and then selecting clones of cells that
added to a total protein to enzyme ratio of 50:1. Western blottingare persistently infected. Such ScN2a cell lines have no
and ELISA were performed as previously described (Scott et al.,
ideal control, since subpopulations of N2a cells may 1989; Peretz et al., 1997). Fab D18 fragment recognizes PrP residues
have been selected during the infection and cloning of 133±157 (Williamson et al., 1998) and was used to measure full-
length MoPrP but not PrP106.ScN2a cells. Because the transmission of RML prions
Artificial Miniprions
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Derivation of N2a and ScN2a Sublines Centricon 10 unit (Amicon; Beverly, MA) to 1 mg/ml and then diluted
to 0.25 mg/ml to obtain CD spectra. Spectra were collected at roomwithout Postinfection Cloning
Mouse neuroblastoma (N2a) cells obtained from the ATCC were temperature with a spectropolarimeter using a 0.1 cm path length.
cloned by dilution into 96-well plates and then expanded into clonal
sublines. Sublines were grown in Dulbecco's modified Eagle's media Negative Stain and Electron Microscopy
with 4.5 g/l glucose supplemented with 10% FBS, 100 U penicillin, Sample preparation was done on carbon-coated 600 mesh copper
and 100 mg/ml streptomycin. Sublines were inoculated into 24- grids that were glow discharged for 30 s prior to staining. Five
well plates with 10% mouse RML brain homogenate diluted 1:10 in microliters of purified PrPSc106 or refolded recombinant PrP106 was
media. Inoculated and uninoculated cells of the same subline were adsorbed to grids for 30±60 s, washed with two drops of 0.1 M and
grown in parallel and split every 3±4 days at a 1:10 dilution in media 0.01 M ammonium acetate each, and stained with two drops of
without inoculum. Multiple sublines were screened for the produc- freshly filtered 2% ammonium molybdate or uranyl acetate. After
tion of protease-resistant PrP by a variation of the histoblot tech- drying, samples were viewed in a Jeol 100CX II electron microscope
nique (Taraboulos et al., 1992). Cells were plated at a 1:10 dilution at 80 kV at a standard magnification of 40,000. The magnification
onto plastic coverslips (Thermonox, Nunc) in 24-well plates and was calibrated using negatively stained catalase crystals.
grown for 4 days. Coverslips were rinsed once in PBS and placed,
cell side up, on dry blotter paper. Nitrocellulose paper soaked in
Acknowledgmentslysis buffer (0.5% sodium deoxycholate, 0.5% Triton X-100, 150 mM
NaCl, 10 mM Tris [pH 7.4]) was firmly pressed onto the coverslips for
We thank C. Petromilli, R. Koehler, and M. Chernock for assistance30 s. The coverslips were then processed as described previously
with transgenic production; H. Serban for assistance with purifica-(Taraboulos et al., 1992). After 30 days in culture, some sublines
tion of PrPSc106; J. Cayetano for processing specimens; D. Han forproduced large amounts of protease-resistant PrP. One of these
DNA sequencing; and D. Groth and P. Tremblay for helpful discus-heavily infected sublines and its corresponding uninoculated sib
sions. This work was supported by grants from the National Insti-(designated N2a.AI.17Sc and N2a.AI.17, respectively) were used for
tutes of Health, the International Human Frontier Science Program,transfection studies.
the American Health Assistance Foundation, and the French Foun-
dation as well as by a gift from the G. Harold and Leila Y. MathersCell Transfection
Foundation. S. S. was supported by the Burroughs Wellcome FundStock cultures of N2a and ScN2a cells were maintained in MEM
Career Development Award and a National Institutes of Health Clini-with 10% FBS, 1% Glutamax (GIBCO BRL), and antibiotics, and
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